Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is reason to think something is not wrong
The first announcement, in November 2020, said:
The merger is expected to close in the first half of 2021...
When is the merger date of MyMD & AKER? Any idea?
AKER is so small company, MyMD is a private company. Not sure why the merger is taking 3 solid months? something is not right...
Have heard nothing about that. Why would they buy or merge with a company millions of dollars in debt with no source of revenue, and in Chapter 11 bankruptcy, from which I'm told there is no recovery for a corporation.
What is interesting is the merger of AKER with MyMd Pharmaceuticals. There's real promise in that. The resulting company (finally) will be on the market as MYMD.
My understanding of all this is limited. Corrections are welcome.
This company is buying/merging with RCPIQ? What happens to the RCPIQ stocks?
I think the value of MYMD-1, and possible successors, is unrecognized, except by a few. The announcements, which only a few expect, should come as a surprise to most.
About time for MyMD Pharma to get on the stick with some announcements! They have been pretty clear that they will begin the 1st two human studies in the first quarter of 2021 utilizing MYMD-1 against depression in Covid and against Sarcopenia. Only 28 days left in the 1st quarter.
MyMD Pharmaceuticals Announces New Data
MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins Discovery
BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery Phenotypic Center of Excellence.
• Data from the translationally relevant study reported ability of MYMD-1 to inhibit key biomarkers associated with fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD)
• Eurofins Discovery human phenotypic screening platform revealed potential of MYMD-1 to be developed as a therapy for fibrosis
Akers Biosciences In (AKER)
3.56 ? -0.37 (-9.41%)
Volume: 681,033 @02/19/21 7:59:57 PM EST
Bid Ask Day's Range
3.52 3.56 3.48 - 3.92
AKER Detailed Quote
AKERS BIOSCIENCES INC filed this SC 13G on Feb 18, 2021
Mainfield Enterprises Inc., British Virgin Islands, owns 1,081,08 shares, which is 5.80% of the voting power.
http://otp.investis.com/clients/us/akers_bioscience/SEC/sec-show.aspx?Type=html&FilingId=14722569&CIK=0001321834&Index=10000
Mainfield Enterprises, Inc. is a business entity registered at Global Legal Entity Identifier Foundation (GLEIF), with entity identifier is 549300AV58Y72FOPIG36. The registration start date is October 31, 2017.
No further info found.
Also, this morning, there is this form 425 SEC filing
http://otp.investis.com/clients/us/akers_bioscience/SEC/sec-show.aspx?Type=html&FilingId=14721863&CIK=0001321834&Index=10000
Seems to document the PR released today. The content is the same.
PR this morning had immediate and temporary effect on price
https://www.businesswire.com/news/home/20210218005243/en/
Within a few minutes after the PR AKER went from $3.85 to $4.74 and immediately back to $3.85. All pre-market so looks like all on less than 20k shares traded.
Pretty strange ... and inconsequential.
AKER price: damaged by a false press release?
Akers Biosciences Responds to Erroneous Earnings Call Press Release
NEW YORK --(BUSINESS WIRE)-- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a company wholly unrelated to the Company. The press release was errantly issued by the newswire services under the Company’s name. The Company has not scheduled any earnings calls. The Company is investigating how this error occurred and reserves all rights to pursue all appropriate remedies upon learning more about the cause of this error.
I doubt very much that MyVET Pharma would be associated with the Akers/MyMD Pharma relationship because of the fact that animal meds don't carry the same respectability of human meds. More likely they would be licensed to an existing veterinary pharmaceutical company in exchange for royalties.
Great find that Nemo Life Sciences and Myridine Inc. were just created this month. May have nothing to do with Akers/MyMD, but interesting non the less. Thanks for sharing.
Supera Pharmaceuticals - an interesting clue. Thanks, knuts4oe.
https://www.corporationwiki.com/p/32t1ju/supera-pharmaceuticals-inc#people
Show that on of the two "Key People" is Jonnie R. Williams. The other is the "registered agent".
What of Jonnie's is being pulled into AKER and then wrapped up in a newly emergent MYMD as it absorbs AKER and becomes the surviving listed company?
map of Jonnie R. Williams' relationships — scroll down
Note Mymd Pharmaceuticals, Inc. and Myvet Pharmaceuticals, Inc.
I wonder if AKER is going to get Myvet too? Lower regulatory if MYMD-1 were to be sold for animal use.
I, personally, am not expecting the Premas connection to amount to anything as we have heard little of any progress lately.
Interesting to note, though, that Supera Pharma and Akers Bio were talking about a merger when MyMD Pharma came on the scene. The plan now is for MyMD Pharma to buy Supera Pharma for about 43 million MyMD shares.
Premas Biotech, D-Crypt, Covid 19, Partnership with Akers
https://www.premasbiotech.com
D-Crypt for Covid 19
Premas specializes in developing recombinant proteins for vaccine development. Such proteins are often “difficult to express proteins” (DTE-Ps). Our innovative D-Crypt platform is optimized for highyield production of DTE-Ps, singularly, or in combination.
Through a partnership with Akers Biosciences, Premas is leveraging DCrypt to develop a multicomponent recombinant protein vaccine against COVID-19.
Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results
Thorofare, New Jersey, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, positive proof of concept results from Animal Studies conducted during a 4 week test of its SARS-CoV-2 vaccine candidate in mice. The test had two primary endpoints, safety and immune response, both of which were met. The candidate was well tolerated and safe in mice that received the intramuscular injection. A robust immune response was also observed.
The study consisted of 50 mice, divided into 10 cohorts dosed with 5, 10 and 20 micrograms of the PRAK-03202 vaccine candidate. The vaccine candidate was generally well tolerated and safe at all doses, with no adverse events reported. The vaccine candidate was safe even at higher doses and generated a robust immune response against the three SARS-Cov2 antigens, S, E, and M. PRAK3202 elicited neutralizing antibody titers levels in all the dose cohorts starting from 5 microgram to 20 microgram dose regimens. After three doses in mice, all the groups' cohorts showed binding antibody levels similar to convalescent patients’ levels.
Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, commented: “We are happy to report that the vaccine candidate study in mice has gone on well, and the results are positive and encouraging. We have engaged with the regulatory authorities in India and are working towards the next steps under their guidance.”
Premas will seek to further characterize the immune response in the near term, while pursuing additional safety studies and later stage animal testing with the goal of an investigational new drug (IND) submission to follow in the U.S. Premas continues to be engaged formally with authorities and the Drug Controller in India. Both Akers and Premas are also communicating with regulators in the United States.
Christopher Schreiber, Executive Chairman of Akers, stated, “We are very encouraged by the immune response and safety milestones met in this study organized with our partner, Premas. We are currently moving towards enhanced dialogue with regulatory bodies in both India and the United States and look forward to communicating updates with our investors in the near term.”
About Premas Biotech
Premas Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates. Premas' key focus areas are infectious diseases, cancer, metabolic disorders and inflammation. Besides D-CryptTM the difficult to express proteins expression platform, Premas’ leading technologies include Axtex-4D™: an ex-vivo tissueoid generation platform and C-Qwence™: a fully human naive India based scFv antibody library. Further information is available on the Company’s website: www.premasbiotech.com
Contact email: contact@premasbiotech.com
After AKER/MyMD announced their reverse merger in November a gaggle of law firms jumped on the bandwagon to come to the rescue of AKER stockholders. I'm wondering if maybe they realized it was such a fantastic opportunity for AKER stockholders that they are now providing the share purchasing that is pushing the stock price ever higher!
Hard to believe that no one is commenting on this performance.
Diagrams: Anatabloc & MYMD-1
https://investorshub.advfn.com/uimage/uploads/2021/2/5/TZFPCZSAQCCVGBGKGY.png
Similar, but with significant differences (count carbons in rings). Biochemists, please speculate.
Oops, forgot to mention that in 2021's 1st quarter one of the studies scheduled to begin involves dosing with MYMD-1, post Covid 19 patients who have developed depression, when they previously had not had a problem with it.
Just noticed this story from Jan. 19th that the DOD has hired CRO Pharm-Olam ($36 million) to test Humira against Covid 19 as an inflammation fighter. In the Akers Biosiences Nov. 18 business report, MyMD Chief Scientific Officer, Dr. Adam Kaplan made it pretty clear that MYMD-1 was triple threat superior to Humira in inflammation reduction, anti-depression, and maintenance of immune system.
https://ih.advfn.com/stock-market/stock-news/84120896/us-department-of-defense-selects-pharm-olam-as-cro
Comments welcomed.
$2.85 NICER
Have totally failed to get my head around what they are proposing in this filing with the SEC.
My first reaction, though, is that this filing was known to the insiders ahead of time, and the stock had a great week. I take this as a good sign.
New Akers Bio SEC filing, Form S-4
Akers Bio has filed the following Form with the SEC:
Jan 15, 2021
Form S-4
I've been telling the RCPIQ board about the AKER board but so far no evidence of a migration.
That's how I've seen it. That 20% may return revenue dwarfing anything else they might have done.
Can't say this is much of a message board, especially since AKER put in quite an impressive performance this week given there was no news to support it. Perhaps the flood of lawyers pursuing AKER for what they think was the lousy deal (80%/20% ownership), discovered that AKER was getting 20% of what may become a mind blowing pharmaceutical powerhouse, and decided to buy into it instead.
Looks different to me. I don't recall seeing "Vaccine" prominently featured.
Is this a new Akers Biosciences website
http://www.akersbio.com/
Akers Biosciences - patent news: regulating tumor necrosis factor-alpha
December 2, 2020 11:37 AM
Akers Biosciences (AKER) +2.5%) proposed merger partner MyMD Pharmaceutical has been issued US Patent No. 10,835,523 B2, covering method of regulating tumor necrosis factor-alpha for cancers, autoimmune and other disorders associated with chronic inflammation, by USPTO. The patent is a continuation of U.S. patent application No. 15/558,094, which was granted with claims for treating diabetes.The issuance is the ninth granted patent for MYMD-1, with an additional 20 applications currently pending worldwide. As previously announced, Akers Biosciences and MyMD Pharmaceuticals agreed to merge as one to focus on developing and commercializing MyMD’s immunotherapy pipeline assets.
From the November Akers presentation
The presentation is at:
https://www.webcaster4.com/Player/Index?webcastId=38815&g=b4677770-9693-447f-9869-a4ac2adbc147
Adam Kaplan's part of the presentation is especially informative. It starts at minute 10.
Dr Adam Kaplan, who earlier in December officially became the Chief Scientific Officer at MyMD Pharmaceuticals, did an excellent job of detailing the significant advantages of dosing with MYMD-1, in the "Akers Biosciences Business Update".
He points out that it is an excellent selective TNFa blocker which makes it a formidable competetor in the $40 billion market for Humira and other TNFa blockers.
It is also an excellent anti-inflammitory which should be useful in treating any disease or medical condition whose name ends in "itis".
It is also a potent anti-depressant which would have application in countless medical conditions.
All of this comes to the Akers/MyMD merger from MyMD. Akers brings only its questionable relationship with Premas for a vaccine, and its ability to raise funds for MyMD. Thus its 20% share in the final MyMD Pharmaceuticals.
Taming the adverse effects of excessive NF-kB
From the paper linked by power walker: "Anatabine ameliorates intestinal inflammation and reduces the production of pro-inflammatory factors in a dextran sulfate sodium mouse model of colitis"
https://journal-inflammation.biomedcentral.com/articles/10.1186/s12950-020-00260-6"
"Anatabine has been shown to inhibit lipopolysaccharide (LPS)-induced pro-inflammatory gene expression as well as NF-kB and STAT3 phosphorylation in human neuroblastoma SH-SY5Y, HEK293, human microglia, and human blood mononuclear cells [33] as well as in the brain and spleen of mouse models of autoimmune encephalomyelitis [31] and Alzheimer’s disease [33]. In SH-SY5Y cells, anatabine also reduced the expression of beta-secretase 1—the rate limiting enzyme for ß-amyloid peptide production, which is a major hallmark of Alzheimer’s disease—through inhibition of NF-kB activation [21].”
Extremely interesting!
I just sent this info to a very capable and unconventional doctor:
Taming the adverse effects of excessive NF-?B seems to be important.
"Anatabine has been shown to inhibit lipopolysaccharide (LPS)-induced pro-inflammatory gene expression as well as NF-?B and STAT3 phosphorylation in human neuroblastoma SH-SY5Y, HEK293, human microglia, and human blood mononuclear cells [33] as well as in the brain and spleen of mouse models of autoimmune encephalomyelitis [31] and Alzheimer’s disease [33]. In SH-SY5Y cells, anatabine also reduced the expression of beta-secretase 1—the rate limiting enzyme for ß-amyloid peptide production, which is a major hallmark of Alzheimer’s disease—through inhibition of NF-?B activation [21].”
Anatabine ameliorates intestinal inflammation and reduces the production of pro-inflammatory factors in a dextran sulfate sodium mouse model of colitis
https://journal-inflammation.biomedcentral.com/articles/10.1186/s12950-020-00260-6
The authors of this paper all seem affiliated with Philip Morris. That company acquired the relevant patents from a company destroyed by the FDA (for no good reason that I could see). Since that time, the product forced off the market by the FDA, has not reappeared. I know people whose lives were damaged significantly by the forced withdrawal of the product, Anatabloc.
All this started when it was noticed that airline stewardesses exposed to second-hand smoke seemed to be less likely to suffer from thyroiditis.
This paper, by Patrizio Caturegli at Johns Hopkins resulted:
"Anatabine ameliorates experimental autoimmune thyroiditis"
https://pubmed.ncbi.nlm.nih.gov/22807490/
Thanks for posting. Looks like competition heating up for MyMD Pharma/Johns Hopkins. Wonder what the patent situation is!
leif and knuts, FWIW - found this article when looking for info on Crohn's Disease and Anatabloc. May be tied into Philip Morris IP on anatabine. Link to full report is on the right side of the page.
https://www.pmiscience.com/library/publication/Anatabine-ameliorates-intestinal-inflammation
leifsmith
I have long been aware of the huge pharma forces who want to see MyMD Pharma fail. It is because of this, that as we approach phase 2 human trials, I would like to see MyMD adopt a licensing and royalty approach, whereby any successful phase 2 human study would be licensed to an appropriate international pharmaceutical company for the required phase 3 human study. This would pass on the huge expense of phase 3 studies to companies that can afford it, while making them partners in this new field of medical science.
"FDA is fully informed of the significance of the MYMD-1 molecule and will likely fast track it."
This would have to be an FDA devoted more to public health than to serving large drug manufacturers. I hope you are right. The MYMD-1 molecule may threaten the sales of many expensive drugs.
To be clear, I am sure there are many people working for the FDA whose objective is genuinely public health.
About your statement "Given the ways of the FDA it may be years before those suffering the effects of chronic inflammation can obtain relief again", I have come to believe that the FDA is fully informed of the significance of the MYMD-1 molecule and will likely fast track it. Only time will tell.
On another note, your mention of izof-texas (eyes of Texas), made me smile as I have been trying to remember his name. He was a big contributor to the anatabine story.
Looks like AKER has broken out of its trading range of 1.95 to 2.05 on no news at a time of year where tax selling pressure usually predominates. Best of luck to all who have a piece of Akers' Biosciences!
Anatabine, possibly MYMD-1, and Chron's disease
This is an excerpt from an old post by izof_texas on a now extinct board, CIGX_VIPGROUP on Yahoo, probably Dec 2014, about the alkaloid based molecule anatabine citrate, and Chron's Disease:
The grandparents of "my Chron's patient", who are my contact in the family, treat me like royalty, and truly seem awe struck with every passing month through which their otherwise-severely-stricken granddaughter goes Chron's free [she was using Anatabloc -leif]. There are now thousands of such stories. So many have been helped already, and we all KNOW it works.
Dr. Patrizio P. Caturegli, Johns Hopkins University School of Medicine takes Jonnie Williams' discovery seriously.
Dr. Patrizio P. Caturegli is an associate professor of pathology at the Johns Hopkins University School of Medicine. An immunopathologist, Dr. Caturegli is the director of the Johns Hopkins Hypophysitis Center and serves on the faculty of the Autoimmune Disease Research Center.
His clinical and research focus is autoimmune diseases of the endocrine glands. These include myocarditis, thyroiditis, hypophysitis, Sjogren''s syndrome, and complete congenital heart blockage.
Dr. Caturegli earned his medical degree from Italy’s Faculty of Medicine E Chirurgua University of Pisa. He completed a residency in endocrinology at the University of Pisa and a residency in pathology at Johns Hopkins. He performed a fellowship in public health at Johns Hopkins where he also earned a M.P.H. from Hopkins’ Bloomberg School of Public Health. He joined the Johns Hopkins faculty in 1999.
He is American Board of Pathology-certified in clinical pathology and has published more than 100 journal articles.
Caturegli P, De Remigis A, Ferlito M, Landek-Salgado MA, Iwama S, Tzou SC, Ladenson PW. Anatabine ameliorates experimental autoimmune thyroiditis. Endocrinology. 2012 Sep;153(9):4580-7
Followers
|
90
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2221
|
Created
|
01/15/15
|
Type
|
Free
|
Moderators |
Akers Biosciences mission is dedicated to solving global health challenges. Akers was founded in 1989 and has over
30 years of success in the health diagnostic industry having developed proprietary, in vitro diagnostic technologies.
In March of 2020, in an attempt to further their mission, Akers announced a strategic partnership with Premas Biotech.
The partnerships primary objective is to focus on novel vaccine candidates.
The emergence of this pandemic offers an opportunity for the company to be a solution in the healthcare space,
one that sets the stage for our next chapter of growth.
Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate
Premas develops novel & transformational technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates.
Akers licensed a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™.
The Premas platform has three key advantages which will set this vaccine candidate apart from industry peers.
Premas successfully cloned three Coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) in the first quarter of 2020 which further differentiates our vaccine candidate.
We aim to provide the immune system with several opportunities to identify the virus; a design concept extremely important for efficacy and our future success.
We held a conference call with Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, in late March.
The transcript, which provides additional information on our philosophy and milestone timeline, can be accessed here.
PIFA® technology is a cutting-edge, patented immunoassay method which rapidly, easily, and accurately detects target antigens or antibodies.
PIFA® technology is based on the selective filtration of microparticles in response to antibody/antigen binding.
Dyed microparticles coated with antigens or antibodies determine the visual signal for the results of the assay.
The presence of a corresponding antibody or antigen in the test sample results in the formation of a matrix of microparticles, which are more susceptible to filtration.
The inability of these matrixed microparticles to move through the filter, and the resulting color change in the reagent mixture,
signal positive reactivity of the test sample (e.g. the presence of target antigens or antibodies).
Key features of PIFA® technology make it advantageous for a broad array of uses:
PIFA® technology is currently used in:
Licensing Availability
PIFA® technology is available for licensing. To inquire about licensing or for technical inquiries, please contact us.
Patent Information
Shs Outstand | 8.72M
|
Insider Trans | -0.83%
|
Book/sh | 2.96 |
Cash/sh | 2.00 |
Debt/Eq NO DEBT | 0.00 |
52W Range | 1.55 - 12.72 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |